Hong Thai is a well-known Thai brand of herbal inhalers widely sold in Southeast Asia. In October 2025, Thailand's Food and Drug Administration announced a recall of Hong Thai Formula 2 after tests found microbial contamination above acceptable limits.
The affected batch, produced in December 2024, exceeded limits for total aerobic microbial count. Malaysia's Health Ministry subsequently banned the product's sale and distribution, and e-commerce platforms were asked to remove listings.
The incident showed how a single contaminated batch can cross borders quickly in a region with integrated online retail. It also raised questions about whether production-scale hygiene controls kept pace with the brand's export growth.
Thailand's FDA recalled the batch; Malaysia banned sales. Contamination crossed borders via e-commerce, so hygiene controls must scale with distribution reach.
Production hygiene controls failed to keep microbial counts within regulatory limits for the affected batch.
The company's quality-assurance process did not catch the contamination before the product reached shelves and online channels.
Export growth into neighbouring markets meant a single batch problem triggered multi-country recalls and bans.
The product was sold on e-commerce platforms that amplified distribution beyond traditional retail tracking.
When a product crosses borders through e-commerce, a single batch failure can become a regional recall — hygiene controls must scale with distribution reach.
Hong Thai recalled the batch and stated other products were unaffected. Regulators in Thailand and Malaysia continued monitoring sales on e-commerce platforms.
FOLLOW THE EVIDENCE